Telescope Innovations Expands Global Reach and Advances Key Projects in Q2 2025

An announcement from Telescope Innovations Corp ( (TSE:TELI) ) is now available.

Telescope Innovations Corp reported its financial results for the second fiscal quarter of 2025, showing a revenue increase to $1 million but an adjusted EBITA loss of $0.4 million. The company is expanding its flagship product, DirectInject-LC™, into China and has hosted a successful user forum with Mettler Toledo, featuring major industry players like AstraZeneca and Genentech. Additionally, Telescope is advancing its Self-Driving Lab project in collaboration with Pfizer, which uses AI and robotics to accelerate pharmaceutical research. The company has also achieved a milestone in its Brine-to-Battery program, producing high-purity lithium carbonate, and its CTO, Jason Hein, received the prestigious 2025 R.U. Lemieux Award.

More about Telescope Innovations Corp

Telescope Innovations Corp is a developer of advanced technologies and services catering to the global pharmaceutical and chemical industries. The company focuses on creating innovative solutions like DirectInject-LC™ and ReCRFT™ to enhance process efficiency and support sustainable practices in these sectors.

YTD Price Performance: -36.59%

Average Trading Volume: 41,175

Technical Sentiment Signal: Buy

Current Market Cap: C$15.07M

See more insights into TELI stock on TipRanks’ Stock Analysis page.